

Sofia Carvalhana, MD

Division of Gastroenterology
Hospital de Santa Maria
Av. Prof. Egas Moniz, 1645-035 Lisboa, Portugal
sofiacarvalhana@msn.com

WORK EXPERIENCE

September, 2023

- 01/2017- present Clinical Assistant at Hospital de Santa Maria**
- Division of gastroenterology
- 01/2017-present Clinical Researcher**
- Steatotic liver disease, Hospital de Santa Maria
- 01/2017-present Assistant at Faculty of Medicine, University of Lisbon, Lisbon, Portugal**
- 01/2023-present Vice President OF APEF (portuguese association for the study of liver disease)**

EDUCATION

- 2011-2016 Gastroenterology residency**
- Hospital de Santa Maria, Lisboa
 - **Training in Endoscopic ultrasound** at Hospital Clínico Universitario de Santiago de Compostela (2014: May to July)
- 2010**
- General Internship at Centro Hospitalar de Lisboa Central, Lisbon
- 2009**
- 2003-2009 Faculty of Medicine, University of Lisbon, Lisbon, Portugal
 - Faculty of Medicine, Paris-Descartes university, Paris, France (Erasmus Program, 2006-2007)

PUBLICATIONS

Book Chapter

- *Epidemiology of Liver Diseases. Regenerative Hepatology and Liver Transplantation.* 2022. Cortez-Pinto H, Carvalhana S, Crespo RR, Craciun A.

Published Manuscripts

- Improving dietary patterns in patients with nonalcoholic fatty liver disease.
Carvalhana S, Machado M, Cortez-Pinto H. *Current Opinion Clinical Nutrition and Metabolism Care* 2012; 15(5):468-7.
- How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound.
Carvalhana S, Leitão J, Alves AC, Bourbon M, Cortez-Pinto H. *Liver International* 2013; 34(6):111-7.
- From Obesity to Fatty Liver/NASH: Two Parallel Epidemics.
Carvalhana S, Cortez-Pinto H. *e-World Gastroenterology News* 2013; vol. 18, issue 2, July 2013.
- Cutaneous Pseudolymphoma in a Patient With Crohn's Disease Under Infliximab: First Report.
Carvalhana S, Gonçalves A, Velosa J. *Journal of Clinical Gastroenterology* 2016 May-Jun; 50(5):436-7
- Hepatitis B and C prevalence in Portugal: disparity between the general population and highrisk groups.
Carvalhana S, Leitão J, Alves AC, Bourbon M, Cortez-Pinto H. *European Journal of Gastroenterology & Hepatology* 2016 Jun;28(6):640-4.
- Acute liver failure due to trazodone and diazepam.
Carvalhana S, Oliveira A, Ferreira P, Resende M, Perdigoto R, Barroso E. *GE Port J Gastreterol*, 2016.
- No Evidence for Lower Levels of Serum Vitamin D in the Presence of Hepatic Steatosis. A Study on the Portuguese General Population
Leitão J, Carvalhana S, et al. *Int J Med Sci.* 2018 Nov 29;15(14):1778-1786.
- Identifying palliative care needs in a Portuguese liver unit.
Carvalho JR, Vasconcelos M, et al *Liver Int.* 2018 Nov;38(11):1982-1987..
- Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals.
Bazerbachi F, Haffar S, et al. *Clin Gastroenterol Hepatol.* 2019 Jan; 17(1):54-64.
- Rectal neuroendocrine tumor – case report.
Simões C, Carvalhana S, Xavier de Brito L, Carrilho-Ribeiro L, Tato Marinho R. *Gastroenterol Hepatol.* 2020 Apr;43(4):209-210.
- Prevalence and risk factors of fatty liver in Portuguese adults
Leitão J, Carvalhana S, et al *Eur J Clin Invest.* 2020 Jun;50(6):e13235.
- What Is the Role of the New Index Relative Fat Mass (RFM) in the Assessment of Nonalcoholic Fatty Liver Disease (NAFLD)?
Machado MV, Policarpo S, Coutinho J, Carvalhana S. et al. *Obes Surg.* 2020 Feb;30(2):560-568.
- No evidence of benefit of routine ascitic fluid analysis in refractory ascites undergoing therapeutic paracentesis.
Sá I et al. *Eur J Gastroenterol Hepatol* 2021 Jun.
- Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Reis D et al. *Eur J Gastroenterol Hepatol* 2021 Dec.
- Clinical, histological and molecular profiling of different stages of alcohol-related liver disease.
Ventura Cots, et al. *GUT* 2022 Sep: 1856-1866.
- Do MAFLD Patients with Harmful Alcohol Consumption Have a Different Dietary Intake?
Policarpo S, Carvalhana S, et al. *Nutrients* 2022 Mar:1335.
- Severe acute autoimmune hepatitis: How to early predict who will not respond to corticosteroids and needs urgent liver transplantation?
João M, Carvalhana S, et al. *Dig Liver Dis.* 2022 Dec:1681-85.
- Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease.
Simão A et al. *JHEP Rep.* 2023 May.
- Liver biopsy online Course from UEG. Drenth J, Cortez-Pinto H, Sofia Carvalhana.

Research Experience

Principal investigator

1. Applicability of *FibroTouch* and Shear Wave elastography (SWE) in stratification of “steatotic Liver Disease - SLD
2. Project E_COR liver: prevalence of liver steatosis in the general population

Co-investigator:

1. Pro-EURO DILI Registry: Creation of a multicenter and multidisciplinary registry of prospective drug-induced liver injury case, PI - Prof. Guruprasad P. Aithal.
2. INTERNATIONAL CLUB ASCITES (GLOBAL - AKI): Characteristics and management of acute kidney injury in hospitalized patients with cirrhosis: A multicenter intercontinental observational prospective study; PI - Prof. Salvatore Piano.
3. SALVE (Study of Alcohol-related liver disease)
4. LITMUS project: Liver Investigation Testing Marker Utility in Steatohepatitis
5. GRIP ON MASH: Global Research Initiative on Patients screening on MASH
6. Translação da sinalização ripk3 para aplicação na doença hepática metabólica, projeto financiado pela FCT (PTDC/MED-FAR/3492/2021)- PI - Prof. Cecília Rodrigues
7. A eficácia do ácido obeticólico e fibratos nos doentes com colante biliar primária, projeto financiado pela hepatologia em rede, cuja investigadora principal é a Dra. Juliana Serrazina
8. O impacto da intervenção nutricional na ascite refratária, cuja investigador principal é a Dra. Juliana Serrazina

Relevant Clinical Trial Experience

Clinical trials		
CI	REGENERATE	Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
CI	TANDEM	Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis
CI	RESOLVE-IT	Phase 3 trial evaluated the effect of elafibranor compared to placebo in patients with biopsy proven NASH
CI	ESSENCE	<i>The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis</i>

CI	FGF-21	<i>Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial</i>
CI	NN9500-4656	<i>Efficacy and Safety Investigation of NNC0194-0499 Co-administered With Semaglutide in Subjects with Non-alcoholic Steatohepatitis: Dose-ranging, Placebo Controlled Trial</i>
CI	NATiV3	<i>A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis 2 (F2)/ Fibrosis 3 (F3) Stage of Liver Fibrosis</i>
CI	BI 1404-0043	<i>Multicenter, double-blind, parallel-group, randomised, 48 weeks, dose-ranging, placebo-controlled phase II trial to evaluate efficacy, safety and tolerability of multiple subcutaneous (s.c.) doses of BI 456906 in patients with non-alcoholic steatohepatitis (NASH) and fibrosis</i>
CI	MK6024-013	A clinical study of Efinopegdutide in participants with precirrhotic NASH
CI	Endo-NASH	<i>A multi-centre, controlled study to evaluate the efficacy and safety of an Endoscopic Sutured Gastroplasty (with Endonima device) in patients with non-alcoholic steatohepatitis (NASH) and fibrosis</i>
CI	ELMWOOD	A fase 2 study to assess safety and effectiveness of Elafibranor in adults with PSC
PI	UX701-CL301	Randomized, Double-Blind, Placebo-Controlled, Multicenter, Seamless, Adaptive, Safety, Dose-Finding, and Phase 3 Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease
PI	EMERAL-3	A Phase III, Randomized, Open Label, Sponsor Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE alone in patients with loco regional Hepatocellular Carcinoma
PI	OPAL	A PAN European Observational Cohort Study Describing Clinical Characteristics, Treatment Patterns and Outcomes in Patients Diagnosed With Hepatocellular Carcinoma (HCC)

LANGUAGES

- Portuguese: Native
- English: Intermediate
- Spanish: Fluent
- French: Fluent